Top Markets
Coin of the day
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
株式のランク #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
株価
$70.50
最終同期: 2025-11-14
時価総額
$7.33B
変化(1日)
0.00%
変化(1年)
116.32%
US
取引 Metsera, Inc. (MTSR)

カテゴリー

Metsera, Inc.(MTSR)の配当利回りの履歴
Metsera, Inc.(銘柄コード: MTSR)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Metsera, Inc.(MTSR)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)